Hemoglobinopathies and stroke: Strategies for prevention and treatment

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 3, 2012, Pages 227-236

  Ali, Noorjahan ^a   Srey, Rothtida ^a   Pavlakis, Steven ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Hemoglobinopathy; Sickle cell disease; Stem cell transplantation; Stroke; Thalassemia; Transfusion treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HYDROXYUREA; RECOMBINANT PLASMINOGEN ACTIVATOR;

ARTICLE; BETA THALASSEMIA; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIET; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXCHANGE BLOOD TRANSFUSION; GRAFT VERSUS HOST REACTION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; LIFESTYLE; MEAN CORPUSCULAR VOLUME; MOYAMOYA DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PHLEBOTOMY; PRIMARY PREVENTION; RECURRENT STROKE; RETICULOCYTE; SECONDARY PREVENTION; SICKLE CELL ANEMIA; STROKE; THALASSEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; THROMBOEMBOLISM; VASCULAR DISEASE;

EID: 84865685213     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0173-x     Document Type: Article

References (23)

1. Prengler M, Pavlakis S, Prohovnik I, Adams R. Sickle cell disease: the neurological complications. Ann Neurol. 2002;51:543-52.
2. Prohovnik I, Hurlet-Jensen A, Adams R, et al. Hemodynamic etiology of elevated flow velocity and stroke in sickle-cell disease. J Cereb Blood F Met. 2009;29:803-10.
3. Yuan J, Bunyaratvej A, Fucharoen S, et al. The instability of the membrane skeleton in thalassemic red blood cells. Blood. 1995;86(10):3945.
4. Succar J, KhalidM, Taher AT. Perspectives: Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis. 2011; 3.
5. Galanello R, Origa R. Review: Beta-thalassemia. Orphanet J Rare Dis. 2010; 5(11).
6. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8, 860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96 (4):488-91. (Pubitemid 44560684)
7. Belisario AR, Rodrigues CV, Martins ML, et al. Coinheritance of α-thalassemia decreases the risk of cerebrovascular disease in a cohort of children with sickle cell anemia. Hemoglobin. 2010;34(6):516-29.
8. Vineeta S, Biswas A, Kumar B, Saxena R. Protein C and Protein S: causative factor for developing a hemorrhagic infarct in a HbE/Beta thalassemia child. Indian J Pediatr. 2010;77(3):316-7.
9. Bishop S, Matheus MG, Abboud MR, et al. Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia. Blood Cells Mol Dis. 2011;47(2):125-8.
10. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Eng J Med. 2003;348:1215-22. (Pubitemid 36359297)
11. Vassilopoulou S, Anagnostou E, Paraskevas G, Spengos K. Etiology and treatment of ischaemic stroke in patients with β-thalassemia major. Eur J Neurol. 2011;18:1426-8.
12. Ware RE, Schultz WH, Yovetich N, et al. Stroke with transfusions changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell Anemia, Stroke, and iron overload. Pediatr Blood Cancer. 2011;57(6):1011-7.
13. Ware RE: Transcranial Dopplers (TCD) with Transfusions Changing to Hydroxyurea. Accessed online at ClinicalTrials.gov on 3 Nov 2011.
14. Lee MT, Piomelli S, Granger S, et al. Stroke prevention trial in sickle cell Anemia (STOP): extended follow-up and final results. Blood. 2006;108 (3):847-52. (Pubitemid 44154616)
15. Musallam KM, Taher AT. Thrombosis in Thalassemia: why are we so concerned? Hemoglobin. 2011;35(5- 6):503-10.
16. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity. Blood. 2010;115(10):1886-92.
17. Taher AT, Mussalam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010;8:2152-8.
18. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle-cell anemia and abnormal results on transcranial Doppler ultrasound. N Eng J Med. 1998;339(1):5-11. (Pubitemid 28304491)
19. Sarode R, Matevosyan K, Rogers ZR, et al. Advantages of isovolemic hemodilution - red cell exchange therapy to prevent recurrent stroke in sickle cell anemia patients. J Clin Apheresis. 2011;26(4):200-7.
20. Lucarelli G, Gaziev J, Isgro A, et al. Allogenic Cellular Gene Therapy in Hemoglobinopathies - Evaluation of Hematopoietic SCT in Sickle Cell Anemia. BoneMarrow Transpl. 2011; E-published ahead of print 18 April 2011.
21. Oberoi S, Bansal D, Singh P, Marwaha RK. Stroke in a young boy with β-thalassemia intermedia secondary to Moyamoya syndrome. J Pediatr Hematol Oncol. 2010;32:568-70.
22. Dhouib N, Mellouli F, Ouederni M, et al. Early onset of cerebrovascular accident in a thalassemia major child. Tunis Med. 2010;88(5):372.
23. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227-76.